Source:http://linkedlifedata.com/resource/pubmed/id/17827067
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2007-11-23
|
| pubmed:abstractText |
In previous reports, we have shown that PBI-1393 (formerly BCH-1393), N,N-Dimethylaminopurine pentoxycarbonyl D-arginine, stimulates cytotoxic T-lymphocyte (CTL) responses both in vitro and in vivo in normal immune status and immunosuppressed mice. Additionally, PBI-1393 was tested for anticancer activity in syngeneic mouse experimental tumor models and it displayed significant inhibition of tumor outgrowths when given in combination with sub-therapeutic doses of cytotoxic drugs (cyclophosphamide, 5-fluorouracil, doxorubicin and cis-platinum). However, the mechanism of action of PBI-1393 was still unknown. Here, we report that PBI-1393 enhances IL-2 and IFN-gamma production in human activated T cells by 51% and 46% respectively. PBI-1393 increases also IL-2 and IFN-gamma mRNA expression as shown by RT-PCR. The physiological relevance of IL-2 and IFN-gamma gene modulation by PBI-1393 is illustrated by the advantageous increase of T cell proliferation (39+/-0.3% above control) and human CTL response against prostate (PC-3) cancer cells (42+/-0.03%). The enhancement of human T cell proliferation and CTL activation by PBI-1393 demonstrates that this compound potentiates the immune response and in this regard, it could be used as an alternative approach to IL-2 and/or IFN-gamma therapy against cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Arginine,
http://linkedlifedata.com/resource/pubmed/chemical/BCH 1393,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase...,
http://linkedlifedata.com/resource/pubmed/chemical/Purines,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factor AP-1
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1521-6616
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
125
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
318-27
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:17827067-Arginine,
pubmed-meshheading:17827067-Cell Proliferation,
pubmed-meshheading:17827067-Cytotoxicity, Immunologic,
pubmed-meshheading:17827067-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:17827067-Gene Expression,
pubmed-meshheading:17827067-Genes, fos,
pubmed-meshheading:17827067-Humans,
pubmed-meshheading:17827067-Interferon-gamma,
pubmed-meshheading:17827067-Interleukin-2,
pubmed-meshheading:17827067-Jurkat Cells,
pubmed-meshheading:17827067-Lymphocyte Activation,
pubmed-meshheading:17827067-Mitogen-Activated Protein Kinase Kinases,
pubmed-meshheading:17827067-Purines,
pubmed-meshheading:17827067-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17827067-Signal Transduction,
pubmed-meshheading:17827067-Th1 Cells,
pubmed-meshheading:17827067-Transcription Factor AP-1
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393.
|
| pubmed:affiliation |
ProMetic BioSciences Inc., 500 Cartier Blvd. West, Suite 150, Laval, Quebec, Canada H7V 5B7. m.allam@prometic.com
|
| pubmed:publicationType |
Journal Article
|